All In Biotech

Drug Trial Radar · NCT07784569

APEX-STROKE Adaptive Platform Trial for Stroke

Integrated Adaptive Platform for EXcellent Clinical Trials in STROKE (APEX-STROKE): A Multi-factorial, Multi-arm, Multi-stage, Randomized, Adaptive Platform Trial

Last checked: Nov 19, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 20,000 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

20,000

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Jun 30, 2029

Study completion Feb 28, 2030

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Huashan Hospital; Chinese PLA General Hospital; Beijing University of Chinese Medicine; Hubei College of Traditional Chinese Medicine; Guangdong Provincial Hospital of Traditional Chinese Medicine
First posted
Aug 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Stroke remains one of the leading causes of death and disability, worldwide. Despite advances in stroke management, only a limited number of acute treatments-including thrombolysis, endovascular thrombectomy, hemicraniectomy, stroke unit care, and aspirin-have demonstrated clear benefit, highlighting the need for widely applicable interventions that improve outcomes. Although randomized controlled trials remain the most reliable method for evaluating treatment efficacy, conventional designs typically assess a single intervention under fixed assumptions and are often costly, resource-intensive, and time-consuming. Platform trials offer a more efficient alternative by enabling the simultaneous evaluation of multiple interventions and the ongoing addition or removal of treatment arms, thereby providing a promising approach to accelerate the identification of effective therapies and transform stroke clinical research. The overarching objective of APEX-STROKE is to identify the treatment/s associated with the highest chance of improving relevant patient outcomes in stroke.

Conditions

  • Stroke

Interventions

  • Early Angong Niuhuang Pill TreatmentDrug

    Participants randomized into the intervention arm receive Angong Niuhuang Pills (ANP, 3 g/pill). The initial dose is given orally for awake patients or via route-specific methods for unconscious patients: if randomized in the ambulance, a 15 mL suspension is administered sublingually (2-2.5 mL every 10 min) with the remainder via nasogastric tube (NGT) post-admission; if randomized in the ED, the suspension is given directly via NGT when indicated. Maintenance dosing follows: one pill twice daily in week 1 and once daily in week 2 (14 days total). Suspensions are prepared by grinding one shelled pill with 15 mL room-temperature saline and must be used within 1 hour.

  • Yiqi Huayu Jiedu MixtureDrug

    Yiqi Huayu Jiedu Mixture is a standardized traditional Chinese medicine oral liquid formulated based on the "benefiting qi, resolving stasis, and detoxifying" therapeutic principle for acute supratentorial hypertensive intracerebral hemorrhage (HICH). Each 100 mL bottle contains Red Ginseng (30 g), Notoginseng (30 g), and Raw Rhubarb (5 g), prepared under GMP standards at Guangdong Provincial Hospital of Chinese Medicine. Administration begins within 48 hours of symptom onset for a total duration of 28 days. For patients able to take oral medication: 33 mL three times daily, taken at least 30 minutes after meals (total 100 mL/day). For patients with dysphagia, insufficient oral intake, unconsciousness, or critical illness: 25 mL via nasogastric tube four times daily (every 6 hours). The formulation aims to restore vital qi, promote blood circulation without damaging healthy qi, and eliminate pathological toxins to facilitate neurological recovery in non-surgical HICH patients.

  • Surgical bundleProcedure

    Early minimally invasive surgery (MIS) is initiated within 8 hours after symptom onset; intensive systolic blood pressure control targeting 130-140 mmHg is achieved within 1 hour post-randomisation and sustained for 7 consecutive days; tranexamic acid (TXA) haemostatic therapy: 1g loading dose infused over 10 minutes, followed by 1g maintenance dose given via 8-hour intravenous infusion, started within 30 minutes after random allocation • Standard guideline routine care only: All patient management is determined per local institutional ICH guidelines; elective MIS is prohibited within 12 hours of symptom onset except for emergency life-saving surgery; no mandatory intensive blood pressure management or routine TXA administration is permitted

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Modified Rankin Scale (mRS) scoreTime frame: Platform level time frame:180 days in Intracerebral Hemorrhage State; 90 days for Ischemic Stroke State. Specific time frame will be included in domain-specific registration.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.